Article Text

Download PDFPDF

178 Tumor neoantigen prioritization from liquid biopsy whole exome sequencing for selected tumor-infiltrating lymphocyte therapy
  1. Urminder Singh1,
  2. Christian E Laing2,
  3. Jacob Gibson1,
  4. Anna Kluew3,
  5. Mahdi Golkaram1,
  6. Sven Bilke1,
  7. Larissa Pikor3,
  8. Nathalie Brassard4,
  9. Matthew Beatty5,
  10. Doris Wiener5,
  11. Brian Czerniecki5,
  12. Shari Pilon-Thomas6,
  13. Simon Turcotte4,
  14. Li Liu1,
  15. Stewart E Abbot3,
  16. Timothy J Langer3,
  17. Grace DeSantis1,
  18. Michael J Ciancanelli3 and
  19. Jeff H Tsai1
  1. 1Illumina, San Diego, CA, USA
  2. 2Turnstone Biologics, Carlsbad, CA, USA
  3. 3Turnstone Biologics, San Diego, CA, USA
  4. 4Université de Montréal, Montreal, QC, Canada
  5. 5Moffitt Cancer Center, Tampa, FL, USA
  6. 6H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Adoptive cell transfer (ACT) of neoantigen-reactive tumor-infiltrating lymphocytes (TILs) is an emerging therapeutic modality for solid cancers. A growing body of clinical data in the TIL-ACT field supports the potential for the identification, selection, and expansion of tumor-reactive T cells to drive objective response in patients. We believe improvement in the method for identifying neoantigens may further increase the breadth and number of tumor-reactive T cells. Tissue biopsy based neoantigen identification can be limiting due to inter- and intra-tumoral heterogeneity and tissue access. Here, we applied whole exome DNA and RNA sequencing on patient liquid biopsy samples to assess the sensitivity of tumor variant detection and prioritization of neoantigen peptides in comparison with tissue data and to potentially improve target yield.

Methods Matched solid tissue and blood samples were collected from 10 patients (CRC, breast, melanoma, or NSCLC). For solid tissue, whole exome sequencing (WES) and transcriptome libraries were prepared using standard tissue protocols. For blood samples, cell-free DNA (cfDNA) and circulating RNA (cRNA) exome libraries were prepared using Illumina RUO library prep kit reagents. Solid tumor variant calling and neoantigen identification were performed by the Turnstone BFX-4101 platform. Liquid biopsy tumor variants and neoantigens were identified using the DRAGENTM Bio-IT platform and pVACtools suite.

Results Ultra-deep WES (>15,000x) of cfDNA resulted in 100% identification of known small variants at 0.5% variant allele frequency (VAF) in control samples, and >80% sensitivity for 0.2% VAF small variant detection in patient samples. Both analytical pipelines achieved 100% sensitivity on a dataset comprising experimentally determined immunogenic peptides. Concordance of somatic variant calls made between the solid and liquid biopsies ranged from 22%-88% concordance in 4 samples, while 6 samples showed no concordance. Further analysis showed a positive correlation between variant concordance and the percent tumor fraction in the liquid biopsy (from 3.6% to 0% tumor fraction in high to low concordance samples, respectively). For those samples with variant level concordance, up to 40% concordance was observed on neoepitope peptide identification between solid and liquid biopsies. In addition, the liquid biopsy data resulted in up to 29x more peptide calls than the solid tissue, suggesting the blood samples may contain unique tumor fragments not detected in solid tissue biopsy.

Conclusions Minimally invasive liquid biopsy is viable for detection of somatic variants with the potential to broaden selection of tumor-reactive TILs and improve objective response.

Acknowledgements Authors U. Singh and C. Laing contributed equally

Ethics Approval This study was approved by the Advarra IRB; IRB#00000971; IRB#21.299. Informed consent was obtained from all participants.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.